Company Profile
Luye Pharma develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and globally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary.
Its portfolio also includes CMNa, a chemical sensitizer for cancer radiotherapy, Boyounuo, an injection for the treatment of various types of cancers, and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia
Maitongna for cerebral edema and edema caused by trauma or surgery, and for treatment of venous reflux disorders. Its portfolio also includes Beixi, an acarbose capsule for Type 2 diabetes mellitus, Seroquel, Seroquel XR, Erzofri, and Rivastigmine Multi-Day Transdermal, Rotigotine transdermal, Fentanyl, and Buprenorphine patches.
Additionally, it offers Rykindo, an injection for the treatment of schizophrenia. Its portfolio also includes Boyoubei, a denosumab injection for the treatment of postmenopausal women with osteoporosis, and Boyouping, a dulaglutide injection for glycemic control in adults, as well as Oukai. Its portfolio also includes Meibirui, Jinyouping, and products. The company distributes and sells pharmaceutical drugs.
Its portfolio also includes develops, manufactures, and commercialises of biologics, and manufactures and sells biopharmaceutical products. Founded in 1994, Luye Pharma is headquartered in Yantai, the People's Republic of China.